Gastric Cancer
Conditions
Interventions
Continuous glucose monitor
Sponsors
Saitama medical university international medical center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients diagnosed with primary gastric cancer Patients who underwent either pyloric gastrectomy, total gastrectomy, or cardia gastrectomy at our hospital Patients aged 20 years or older at the time of consent acquisition Patients who provided written consent to participate in this study
Exclusion criteria
Exclusion criteria: Patients taking oral hypoglycemic agents or insulin on a regular basis Patients experiencing severe complications or side effects from surgery or adjuvant chemotherapy Patients with severe hepatic impairment Patients with severe renal impairment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood glucose fluctuations measured using a continuous glucose monitoring device. It will be evaluated at one year postoperatively. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient background (age, sex, stage, PS, comorbidities), surgical outcomes (surgical procedure, blood loss, operating time, postoperative hospital stay, postoperative complications), adjuvant therapy, pathological diagnosis, weight change, blood test data changes (serum albumin, total cholesterol, lymphocyte count, etc.), symptom score based on PGSAS. Blood tests, blood draws, and PGSAS questionnaires will be evaluated at the one-year postoperative mark, similar to blood glucose measurements. | — |
Countries
Japan
Contacts
Public ContactMasatoshi Yoshizawa
Saitama medical university international medical center Digestive surgery
Outcome results
None listed